Cortechs.ai | Neuroimaging biomarkers for AD

Neuroimaging biomarkers for AD

Structural Functional And Molecular Neuroimaging Biomarkers For Alzheimer’s Disease

Magnetic resonance spectroscopy (MRS) has long showed promise for detection of regional chemical changes associated with neurodegeneration, infl ammation, or gliosis, and so it has been a technique of interest for detecting such changes in AD. It provides information about relative concentrations of key chemicals, such as N acetylaspartate, creatinine, and myoinositol, and there is strong evidence that the regional concentration of these chemicals varies with the neurodegeneration seen in AD. (2013).

[button]Download[/button]

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top